Apolipoprotein E and Atherosclerosis: From Lipoprotein Metabolism to MicroRNA Control of Inflammation. by Bouchareychas, Laura & Raffai, Robert L
UCSF
UC San Francisco Previously Published Works
Title
Apolipoprotein E and Atherosclerosis: From Lipoprotein Metabolism to MicroRNA Control 
of Inflammation.
Permalink
https://escholarship.org/uc/item/3z67f04v
Journal
Journal of cardiovascular development and disease, 5(2)
ISSN
2308-3425
Authors
Bouchareychas, Laura
Raffai, Robert L
Publication Date
2018-05-23
DOI
10.3390/jcdd5020030
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Journal of
Cardiovascular 
Development and Disease
Review
Apolipoprotein E and Atherosclerosis: From
Lipoprotein Metabolism to MicroRNA Control
of Inflammation
Laura Bouchareychas ID and Robert L. Raffai *
Department of Surgery, University of California San Francisco & Veterans Affairs Medical Center,
4150 Clement Street, San Francisco, CA 94121, USA; laura.bouchareychas@ucsf.edu
* Correspondence: robert.raffai@ucsf.edu; Tel.: +1-415-221-4810 (ext. x22541)
Received: 12 April 2018; Accepted: 18 May 2018; Published: 23 May 2018


Abstract: Apolipoprotein (apo) E stands out among plasma apolipoproteins through its
unprecedented ability to protect against atherosclerosis. Although best recognized for its ability
to mediate plasma lipoprotein clearance in the liver and protect against macrophage foam cell
formation, our recent understanding of the influence that apoE can exert to control atherosclerosis
has significantly widened. Among apoE’s newfound athero-protective properties include an ability
to control exaggerated hematopoiesis, blood monocyte activation and aortic stiffening in mice with
hyperlipidemia. Mechanisms responsible for these exciting new properties extend beyond apoE’s
ability to prevent cellular lipid excess. Rather, new findings have revealed a role for apoE in regulating
microRNA-controlled cellular signaling in cells of the immune system and vascular wall. Remarkably,
infusions of apoE-responsive microRNA mimics were shown to substitute for apoE in protecting
against systemic and vascular inflammation to suppress atherosclerosis in mice with hyperlipidemia.
Finally, more recent evidence suggests that apoE may control the release of microvesicles that could
modulate cellular signaling, inflammation and atherosclerosis at a distance. These exciting new
findings position apoE within the emerging field of intercellular communication that could introduce
new approaches to control atherosclerosis cardiovascular disease.
Keywords: apolipoprotein E; hyperlipidemia; atherosclerosis; inflammation; microRNA
1. Introduction
Apolipoprotein (apo) E is recognized for its unparalleled ability to suppress atherosclerosis [1–3].
Beyond its participation in the removal of atherogenic remnant lipoproteins from plasma, apoE is
known to exert an influence on numerous cells including those of the vessel wall, the immune system
and the bone marrow. The expression of apoE in the macrophage has long been recognized to suppress
atherosclerosis by preventing foam cell formation in the vessel wall [4,5]. More recently, apoE has
been shown to suppress myelopoeisis [6] and the expansion and activation of monocytes in the
circulation of hyperlipidemic mice [7]. The underlying mechanism for this new protective property
has largely been ascribed to the lipid efflux capacity of apoE both through its cellular expression [6]
and by its ability to enhance the lipid efflux capacity of plasma HDL [7]. Beyond its properties
to maintain lipid homeostasis in the circulation and immune cells, apoE is also known to control
cellular signaling via its interaction with apoE receptors and heparin sulfate proteoglycans (HSPG).
Through such cell-signaling properties, apoE has been shown to control biological effects ranging
from macrophage plasticity to smooth muscle cell proliferation and endothelial cell activation [5].
An exciting new cell-signaling property of apoE introduces a novel paradigm for inflammation control
in the cardiovascular system. Lipoprotein-associated apoE was found to suppress smooth muscle cell
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proliferation and aortic stiffening by regulating the expression of microRNA including by reducing
levels of miR-221/222 and increasing levels of miR-145 respectively [8,9]. Furthermore, apoE was found
to influence levels of cellular miR-146a in monocytes and macrophages to suppress NF-κB–driven
inflammation and atherosclerosis in hyperlipidemic mice [10]. Collectively, such recent findings
broaden our understanding and appreciation for apoE in its capacity to suppress atherosclerosis
beyond modulating plasma and cellular lipid levels. This review article summarizes many of the
well-accepted and more recently described atheroprotective properties of apoE. It also serves to
introduce tantalizing new evidence linking apoE to extracellular RNA transport and intercellular
signaling that could offer new therapeutic approaches for this rampant cardiovascular disease.
2. ApoE and Plasma Lipid Homeostasis
Decades of research conducted by Robert W. Mahley and Karl H. Weisgraber, along with
their co-workers at the J. David Gladstone Foundation laboratories in San Francisco, California,
led to seminal findings in the biology of apoE [11]. Specifically, their studies revealed structural
and functional components of apoE that contribute to its ability to promote the clearance of
cholesterol-rich plasma lipoproteins by the liver [11–13]. The “secretion-capture” process of apoE
was identified as a fundamental property of hepatocyte-derived apoE that enables the protein
to efficiently clear atherogenic plasma lipoproteins within the Space of Disse in the liver [14].
Although extra-hepatic sources of apoE have been shown to contribute to lipoprotein clearance
by the liver [15], studies conducted with the hypomorphic apoE (Apoeh/h) mouse model of conditional
apoE expression, also termed the HypoE mouse [16], demonstrated that even a very small amount
of hepatocyte-derived apoE is highly effective in clearing atherogenic lipoproteins from plasma [17].
The unique phenotype of inducible apoE expression displayed by HypoE mice (Figure 1) offered new
opportunities to investigate the importance in the source of apoE in the process of atherosclerosis.
Furthermore, temporal Cre-mediated gene repair of the Apoeh/h locus revealed a role for apoE in
promoting the regression of atherosclerosis beyond reducing plasma lipid levels [18]. Breeding Apoeh/h
mice with mice deficient in LDL receptor gene expression led to new opportunities to study the process
of apoE in atherosclerosis progression [7] and its regression [19]. Likewise, breeding Apoeh/h mice
with mice deficient in the scavenger receptor class B type-1 (SRB1−/−Apoeh/h mice) led to a model
of diet-induced occlusive coronary atherosclerosis, myocardial infarction and fatal ischemic heart
disease [20,21]. Remarkably, temporal repair of the HypoE allele in SRB1−/−Apoeh/hMx1-Cre mice
led to a model of chronic heart failure in mice that survive episodes of diet-induced myocardial
infarction [22]. More recently, breeding SRB1−/−Apoeh/h mice with the K14-RacV12−/+ mouse
model of human psoriasis led to studies of chronic skin inflammation in accelerated diet-induced
atherosclerosis [23]. Conditional Apoe gene expression in HypoE mice and its derivatives thus
represents a valuable tool to model the impact of hyperlipidemia in atherosclerosis cardiovascular
disease and to study the contribution of apoE in these disorders.
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Figure 1. The Hypomorphic Apoeh/h allele: The wildtype mouse Apoe allele is composed of 4 exons 
on chromosome 7. A neomycin resistance cassette flanked by loxP sites introduced into intron 3 
reduces ApoE expression levels of the gene in all tissues, presumably by interrupting RNA splicing. 
Cre-mediated removal of neo cassette restores Apoe expression to physiological levels. 
3. ApoE4 Domain Interaction and Atherosclerosis 
A caveat to all studies of the HypoE mouse model detailed above rests with their expression of 
an apoE4-like form of mouse apoE called Arg-61 apoE, engineered to reproduce a unique biophysical 
property of apoE4 called domain interaction [24]. Prior studies have shown that Arg-61 apoE 
reproduces the VLDL preference of apoE4 while retaining high affinity to the LDLR [24]. Studies by 
Eberlé et al. [25] demonstrated that apoE4 domain interaction contributes to accelerate diet-induced 
atherosclerosis in HypoE mice expressing the Arg-61 (ApoeR61h/h) alleles. Domain interaction raised 
plasma apoB-lipoprotein levels and reduced apoE secretion in peritoneal macrophages while 
enhancing their cellular activation, including by raising cell surface MHC-II expression [25]. Thus, 
phenotypes of inflammation and atherosclerosis reported in studies making use of HypoE mice and 
its derivatives could have been influenced through the expression of the Arg-61 apoE allele. Such 
effects can be further explored through studies of HypoE mice expressing wildtype mouse ApoeT61h/h 
alleles that do not display apoE4 Domain Interaction and therefore are a model for human apoE3 
[24,25]. 
4. Pleiotropic Properties of ApoE in Inflammation and Atherosclerosis Control 
Beyond its pivotal role in regulating lipoprotein cholesterol transport, apoE is recognized for its 
capacity to suppress atherosclerosis by exerting multiple effects on almost every cell type found in 
the arterial wall [1,5,26]. Although macrophages are recognized as the main source of apoE in 
atheroma [4,27,28], newer findings have reported apoE expression by monocytes as a contributing 
source of hyperlipidemia and atherosclerosis regulation [10,29]. Cellular cholesterol accumulation in 
macrophages and their monocyte precursors leads to oxysterol-mediated up-regulation of liver X 
receptor (LXR) target genes that include ApoE, ABCA1 and ABCG1 that participate in eliminating 
pools of cellular cholesterol and increasing a local pool of extracellular apoE in the artery [29–32]. 
Sustained expression of apoE in the vessel wall in a murine model of macrophage death suppression 
established the importance of this source of apoE in atherosclerosis control [29]. ApoE is also known 
to reduce lipid oxidation [33], the activation of endothelial cells [34] and platelets [35], the 
phagocytotic clearance of apoptotic bodies [36], and suppresses the migration and proliferation of 
vascular smooth muscle cells [37,38]. Remarkably, these protective effects persist even when apoE is 
Figure 1. The Hypomorphic Apoeh/h allele: The wildtype mouse Apoe allele is composed of 4 exons
on chromosome 7. A neomycin resistance cassette flanked by loxP sites introduced into intron
3 reduces ApoE expression levels of the gene in all tissues, presumably by interrupting RNA splicing.
Cre- ediated re oval of neo cassette restores Apoe expression to physiological levels.
3. ApoE4 Domain Interaction and Atherosclerosis
A caveat to all studies of the HypoE mouse model detailed above rests with their expression of an
apoE4-like form of mouse apoE called Arg-61 apoE, engineered to reproduce a unique biophysical
property of apoE4 called domain interaction [24]. Prior studies have shown that Arg-61 apoE
reproduces the VLDL preference of apoE4 while retaining high affinity to the LDLR [24]. Studies by
Eberlé et al. [25] demonstrated that apoE4 domain interaction contributes to accelerate diet-induced
atherosclerosis in HypoE mice expressing the Arg-61 (ApoeR61h/h) alleles. Domain interaction raised
plasma apoB-lipoprotein levels and reduced apoE secretion in peritoneal macrophages while enhancing
their cellular activation, including by raising cell surface MHC-II expression [25]. Thus, phenotypes of
inflammation and atherosclerosis reported in studies making use of HypoE mice and its derivatives
could have been influenced through the expression of the Arg-61 apoE allele. Such effects can be
further explored through studies of HypoE mice expressing wildtype mouse ApoeT61h/h alleles that
do not display apoE4 Domain Interaction and therefore are a model for human apoE3 [24,25].
4. Pleiotropic Properties of ApoE in Inflammation and Atherosclerosis Control
Beyond its pivotal role in regulating lipoprotein cholesterol transport, apoE is recognized for
its capacity to suppress atherosclerosis by exerting multiple effects on almost every cell type found
in the arterial wall [1,5,26]. Although macrophages are recognized as the main source of apoE in
atheroma [4,27,28], newer findings have reported apoE expression by monocytes as a contributing
source of hyperlipidemia and atherosclerosis regulation [10,29]. Cellular cholesterol accumulation
in macrophages and their monocyte precursors leads to oxysterol-mediated up-regulation of liver X
receptor (LXR) target genes that include ApoE, ABCA1 and ABCG1 that participate in eliminating
pools of cellular cholesterol and increasing a local pool of extracellular apoE in the artery [29–32].
Sustained expression of apoE in the vessel wall in a murine model of macrophage death suppression
established the importance of this source of apoE in atherosclerosis control [29]. ApoE is also known to
reduce lipid oxidation [33], the activation of endothelial cells [34] and platelets [35], the phagocytotic
clearance of apoptotic bodies [36], and suppresses the migration and proliferation of vascular smooth
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muscle cells [37,38]. Remarkably, these protective effects persist even when apoE is present at
sub-physiological levels that lead to hyperlipidemia [27,39–41]. Studies have also shown that apoE
can suppress mitogen-activated proliferation of CD4 and CD8 T cells [42–44], and antigen-dependent
T cell activation by reducing the density of major histocompatibility (MHC) class II molecules and
co-stimulatory molecules on macrophages [45]. ApoE is also known to regulate innate immunity [46]
and the susceptibility to bacterial infections [47,48] and sepsis [49,50]. Interestingly, apoE expression
by macrophages is itself subject to regulation by inflammatory cytokines. While TNFα increases apoE
expression [51], IFNγ reduces apoE expression [52]. Thus, the diversity of cytokines generated within
the arterial wall may impact the protective potential of apoE on atherosclerosis development.
5. ApoE Regulation of Macrophage Polarity and Inflammatory Phenotypes
Macrophages are plastic cells that exist as heterogeneous populations in atherosclerotic
lesions [53,54]. Their polarity is driven through environmental cues including plasma lipid levels,
cytokines, and oxidized lipids [55]. Pro-inflammatory M1 and the more recently described Mox
macrophages contribute to plaque growth and instability [56,57], while alternatively activated M2
and Mres macrophages have been shown to participate in the regression of atherosclerosis [58,59]
and resolution of inflammation [60]. Through interactions with the cell surface receptors VLDLR or
ApoER2, apoE has been shown to reduce the expression levels of M1 macrophage markers including
iNOS while increasing the expression of M2 markers including arginase-1 [61]. Through such signaling,
apoE reduces the macrophages sensitivity to IFNγ, suppressing their secretion of pro-inflammatory
cytokines and enhances their propensity for migration. In contrast, such signaling via apoE enhances
the M2-like properties of macrophages including phagocytosis and the secretion of anti-inflammatory
cytokines [61] that are recognized in the control of atherosclerosis progression and its regression [62].
6. Cell-Derived ApoE and Control of Lipid-Induced HSPC Proliferation
Studies by Yvan-Charvet et al. revealed that impaired cellular cholesterol efflux results in
the hyperproliferation of hematopoietic stem and multipotential progenitor cells (HSPCs) in the
bone marrow, causing myeloproliferation and monocytosis [63]. HSPC hyperproliferation in
hyperlipidemic mice was linked to increased cholesterol-rich lipid rafts that enhanced the density of
cytokine receptors in the plasma membrane and proliferative signaling [63]. Interestingly, apoE was
found to be expressed by HSPCs, which led to its becoming anchored on the cell surface through
interactions with HSPG, similar to how it is known to occur on hepatocytes [14] and macrophages [64],
where it participates in cellular lipid transport (Figure 2). ApoE-mediated HSPC proliferative
control was shown to be mediated through cellular lipid efflux via ABCA1 and ABCG1, as in
their absence, pools of cell surface apoE no longer suppressed HSPC hyperproliferation in mice
with dyslipidemia [6]. Although physiological levels of circulating apoE and apoA-I were not
found to suppress HSPC proliferation in hyperlipidemic Ldlr−/− mice, infusions of larger amounts
of recombinant apoA-I containing HDL particles did reduce HSPC proliferation and concomitant
monocytosis. The “therapeutic” effect of HDL infusion on suppressing HSPC proliferation was
associated with reduced plasma membrane lipid rafts and IL-3/GM-CSF receptor density [6].
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Figure 2. ApoE suppression of lipid-induced HSPC hyperproliferation. Hyperlipidemia promotes 
HSPC proliferation by enriching the plasma membrane with cholesterol-rich lipid rafts and the IL-
3/GM-CSF receptor to drive growth signaling. ApoE produced by HSPC can become anchored to the 
cell membrane via HSPG where it promotes cholesterol efflux via HDL containing apoA1 via ABCA-
1 and ABCG-1. This reduces cell surface lipid rafts, and thereby growth signaling. HDL containing 
apoE could also suppress HSPC proliferation by promoting cholesterol efflux via ABCG-1. 
7. Plasma ApoE and Control of Monocyte Activation in Hyperlipidemic Mice 
Human hyperlipidemia often results in apoE accumulation in plasma and atheroma [11,65]. 
Because of its potent ability to reduce plasma lipid levels in rodents, investigating how elevated apoE 
levels contribute to regulate atherosclerosis in the setting of hyperlipidemia has been challenging. 
Work from the authors’ laboratory introduced new strains of mice derived from the HypoE mouse 
model of conditional Apoe expression to address this question [7]. Deleting LDL receptor expression 
in HypoE mice to generate Apoeh/hLdlr−/− mice led to spontaneous hyperlipidemia that was similar to 
levels seen in Apoe−/−Ldlr−/− mice that completely lack apoE. Remarkably, chow-fed Apoeh/hLdlr−/− mice 
displayed plasma apoE levels that exceeded those of Ldlr−/− mice, suggesting a defect in remnant 
lipoprotein clearance [7]. Elevated levels of circulating apoE in the hyperlipidemic plasma of 
Apoeh/hLdlr−/− mice led to a significant reduction in atherosclerosis in both the aortic root and the 
abdominal aorta of 5-month-old mice [7]. At that time-point, apoE substantially reduced blood 
leukocyte counts and led to a two-fold reduction in pro-inflammatory Ly6Chigh monocytes. ApoE 
accumulation in hyperlipidemic plasma also led to reduced neutral lipid levels in monocytes, 
especially among Ly6Chigh monocytes that displayed reduced levels of adhesion molecules involved 
in vascular recruitment. 
8. ApoE Remodels HDL and Improves their Function in Hyperlipidemia 
The protective effects apoE on reducing blood leukocyte counts, monocyte lipid accumulation 
and activation in Apoeh/hLdlr−/− mice was initially linked to its impact on plasma lipoprotein 
remodeling. In contrast to Apoe−/−Ldlr−/− mouse plasma, where apoA-I distributed among all classes of 
lipoproteins, in Apoeh/hLdlr−/−, mouse plasma apoE distributed almost exclusively to VLDL, displacing 
apoA-I and concentrating it on HDL [7]. This resulted in a two-fold increase in HDL-associated 
cholesterol and apoA-I in Apoeh/hLdlr−/− mice (Figure 3). Not surprisingly, Apoeh/hLdlr−/− mouse HDL 
were found to be more potent at promoting cholesterol efflux form cultured macrophages, and this 
effect was proposed to protect monocytes from lipid excess. By increasing apoA-I rich HDL in 
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Apoeh/hLdlr−/− mouse HDL were found to be more potent at promoting cholesterol efflux form
cultured macrophages, and this effect was proposed to protect monocytes from lipid excess.
By increasing apoA-I rich HDL in plasma, circulating apoE could also have suppressed HSPC
hyperproliferation in Apoeh/hLdlr−/− mice (Figure 2). Moreover, minor apoE-only HDL such as
γLpE could have exerted profound protective effects on reducing cell membrane cholesterol and lipid
rafts and thereby growth signaling in HSPCs from these mice. Conversely, the reduced expression
levels of the Apoe allele in Apoeh/hLdlr−/− mice likely extended to HSPCs and could explain the more
modest reduction in monocytosis observed in this study [7] than in findings reported by Murphy
et al. in which HSPC expressed physiological levels of apoE [6]. It is also important to question
whether beneficial effects of apoE on suppressing hematopoiesis and monocyte activation derive solely
from cellular lipid loss. Hematopoiesis control via apoE could also derive from cellular signaling
including through the VLDLR as described by Baitsch et al. [61], or microRNA regulatory pathways,
as discussed below.
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activation, in monocytes and macrophages; (B) Cellular ApoE expression and its accumulation in 
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cellular lipids from circulating monocytes and macrophages, reducing cellular activation and the 
expression of cell surface adhesion molecules that contribute to vascular recruitment and 
atherosclerosis. 
9. ApoE Regulation of Myeloid Cells Signaling via MicroRNA: Impact on Atherosclerosis 
MicroRNAs have emerged as key regulators of inflammation and inflammatory diseases 
including atherosclerosis [66–68]. Studies from the authors’ laboratory [10] have recently uncovered 
evidence linking cellular apoE expression to enhanced miR-146a levels in macrophages and 
monocytes that suppress inflammation and atherosclerosis in hyperlipidemic mice (Figure 4). Indeed, 
among the numerous microRNA that are known to regulate inflammation, miR-146a is established 
as a critical regulator of myeloid cell activation and expansion [69–71]. It also controls the balance 
between pro- and anti-inflammatory monocytes by down-regulating the expression of the 
transcription factor RelB that controls the proliferation of Ly-6Chigh monocytes, which are recognized 
for their inflammatory [72] and atherogenic properties [73]. MiR-146a is also recognized for its ability 
to potently suppress acute inflammatory challenges by reducing TLR-driven NF-κB signaling in 
macrophages and in hematopoietic stem cells [69,71,74]. This function is crucial to prevent an 
immunological overload and fatal inflammation following a bout of sepsis or LPS injection [70]. The 
Figure 3. ApoE reduces lipid accumulation and the activation of monocytes and macrophages in
hyperlipidemic mice. (A) In the absence of apoE, apoA1 distributes to both VLDL and HDL reducing the
cholesterol efflux capacity of HDL resulting in cellular lipid accumulation, and thereby NF-κB act vation,
in monoc t s and acroph g s; (B) Cellula ApoE expression and it accumulation in hyperlipidemic
plasma leads to its preferential binding to VLDL causing the displacement of apoA1 that re-distributes
to HDL. This increases apoA1-rich HDL in plasma, which more effectively removes cellular lipids from
circulating monocytes and macrophages, reducing cellular activation and the expression of cell surface
adhesion molecules that contribute to vascular recruitment and atherosclerosis.
9. ApoE Regulation of Myeloid Cells Signaling via MicroRNA: Impact on Atherosclerosis
MicroRNAs have emerged as key regulators of inflammation and inflammatory diseases including
atherosclerosis [66–68]. Studies from the authors’ laboratory [10] have recently uncovered evidence
linking cellular apoE expression to enhanced miR-146a levels in macrophages and monocytes that
suppress inflammation and atherosclerosis in hyperlipidemic mice (Figure 4). Indeed, among the
numerous microRNA that are known to regulate inflammation, miR-146a is established as a critical
regulato of myel id cell activation a d expansi n [69–71]. It also controls the balance betwee pro- and
anti-inflammatory onoc tes by own-regulating th expression of the transcription factor RelB that
controls the proliferation of Ly-6Chigh monocytes, which are recognized for their inflammatory [72]
and atherogenic properties [73]. MiR-146a is also recognized for its ability to potently suppress
acute inflammatory challenges by reducing TLR-driven NF-κB signaling in macrophages and in
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hematopoietic stem cells [69,71,74]. This function is crucial to prevent an immunological overload and
fatal inflammation following a bout of sepsis or LPS injection [70]. The control of miR146a expression
by apoE provides new insight to explain the susceptibility of Apoe−/− mice to atherosclerosis [75,76]
and sepsis [46,77]. Interestingly, the ability of apoE to regulate cellular microRNA levels is not limited
to myeloid cells. Studies have shown that apoE can reduce levels of miR-221/222 in smooth muscle cell
to suppress their proliferative capacity [8] while increasing levels of miR-145 to reduce aortic stiffening
and thereby the recruitment of monocyte-derived macrophages to the vessel wall [9]. Because apoE is
known to suppress endothelial cell activation [34], it is possible that it could be doing so in part by
raising cellular miR-146a levels that can suppress endothelial dysfunction [78]. Such enrichment of
miR146a or even apoE itself in endothelial cells could derive from its delivery via exosomes secreted
by macrophages (Figure 4). Support for such concepts comes from the results of a study that recently
reported the delivery of macrophage-apoE to tumor cells via exosomes that controlled migratory
phenotypes [79].
Collectively, findings of apoE-regulation of microRNA signaling provide new mechanistic
properties to explain its capacity to suppresses atherosclerosis beyond reducing plasma lipid levels or
enhancing cellular lipid efflux. In fact, this new mode of cellular regulation by apoE could explain
results of earlier reports that documented its capacity to suppress type I inflammation [46] and
promote atherosclerosis regression beyond reducing plasma lipid levels [19]. Additionally, because
apoE participates in plasma lipoprotein remodeling [7], it could impact their microRNA repertoire and
ultimately their delivery to target cells (Figure 4), a process that has recently been shown to suppress
vascular inflammation in mice [80]. Preliminary data from the authors’ laboratory support this
possibility that could in part explain the observed reduced endothelial activation and atherosclerosis
in hyperlipidemic mice that accumulate apoE in plasma [7]. Together, such findings highlight the
complexity through which apoE contributes to regulate microRNA signaling to suppress inflammation
and atherosclerosis in the absence of plasma lipid reduction. Future studies will be required to address
the relevance of this and other protective mechanisms through which apoE can control atherosclerosis
in humans including in an isoform-specific manner.
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Figure 4. ApoE regulation f NF-κB signaling in cytes and macrophages v a microRNA. ApoE
expression has been shown to c ntrol myeloid c tivation by increasing cellular miR-146a that
suppresses TLR-driven NF-κB signaling by reducing levels of TRAF6 and IRAK1 [10]. Further studies
will be required to explore whether lipoprotein associated apoE can contribute to microRNA regulation
through receptor-mediated signaling, and whether the source of apoE impacts on the microRNA
content of exosomes and plasma lipoproteins to communicate signaling at a distance.
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10. Conclusions
More than 40 years after its discovery, apoE remains actively studied owing to its remarkable
number of emerging pleiotropic properties, many of which contribute to the suppression of inflammation
and atherosclerosis. Far beyond its well-known ability to clear cholesterol-rich lipoproteins from plasma
or enhance the release of cellular lipid from macrophage foam cells, apoE is increasingly being
recognized for its ability to control cellular signaling in cells of the immune system and vessel wall.
Our understanding of the vast cellular regulatory networks controlled by apoE is just beginning to
emerge. Past and more recent evidence demonstrates that apoE can impact numerous forms of cellular
signaling that now include microRNA controlled cellular gene expression, including in monocytes,
macrophages and smooth muscle cells. Therefore, monitoring apoE-relevant microRNA signatures
may provide new biomarkers for early atherosclerosis detection. Furthermore, the use of mimics
and antagonists of apoE-relevant microRNA delivered via nanoparticles including liposomes and
exosomes, could offer new therapeutic approaches to control atherosclerosis cardiovascular diseases.
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